Genprex, Inc.

GNPX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-16.2M $-21.1M $-30.9M $-23.7M $-20.7M $-17.9M $-10.7M $-12.4M
Depreciation & Amortization — — — — — — — —
Depreciation $0 $6.7K $15.0K $25.6K $22.5K $22.8K $13.1K $5.9K
Amortization — $773.5K $0 — — — — —
Stock-Based Compensation — $3.3M $5.4M $4.7M $5.3M $4.2M $3.5M $5.4M
Net Cash from Operating Activities $-15.3M $-17.9M $-24.7M $-17.6M $-14.3M $-13.9M $-6.9M $-6.8M
Investing Activities
Capital Expenditures — — — $0 $31.7K $17.6K $33.4K $22.4K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $0 $774.6K $-71.2K $-59.7K $-83.8K $-2.3M $-946.9K $-103.3K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $21.5M $12.0M $10.6M $6.4K $25.7M $41.6M $1.3M $15.4M
Net Change in Cash $6.2M $-5.1M $-14.2M $-17.7M $11.3M $25.3M $-6.6M $8.4M
Free Cash Flow — — — $-17.6M $-14.3M $-14.0M $-7.0M $-6.9M
← Newer Page 1 of 2 Older →